These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 31021918

  • 1. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
    Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H.
    Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
    [Abstract] [Full Text] [Related]

  • 2. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 3. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
    Ayati N, Lee ST, Zakavi SR, Cheng M, Lau WFE, Parakh S, Pathmaraj K, Scott AM.
    J Nucl Med; 2021 Jul 01; 62(7):926-933. PubMed ID: 33246978
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 01; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J, Song Q, Guo F, Du R, Fang H, Kang J, Lu Z.
    Nucl Med Commun; 2022 Jun 01; 43(6):717-724. PubMed ID: 35354781
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy.
    Pierson C, Grinchak T, Sokolovic C, Holland B, Parent T, Bowling M, Arastu H, Walker P, Ju A.
    Radiat Oncol; 2018 Feb 27; 13(1):34. PubMed ID: 29486779
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K, Yamaguchi O, Naruse I, Umeda Y, Honda T, Watanabe S, Ichikawa K, Yanagisawa S, Kasahara N, Higuchi T, Hashimoto K, Miura Y, Shiono A, Mouri A, Imai H, Iizuka K, Ishizuka T, Minato K, Suda S, Kagamu H, Mori K, Seki N, Kuji I.
    Cancer Imaging; 2023 Mar 01; 23(1):23. PubMed ID: 36859341
    [Abstract] [Full Text] [Related]

  • 17. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Hendel HW.
    J Nucl Med; 2013 Jul 01; 54(7):1026-31. PubMed ID: 23572497
    [Abstract] [Full Text] [Related]

  • 18. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr 01; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

  • 19. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 20. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, Yang CT, Cheng NM, Su TP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Nov 05; 43(12):2155-2165. PubMed ID: 27260520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.